Diffusion Pharmaceuticals (DFFN) Announces Quarterly Earnings Results

Diffusion Pharmaceuticals (NASDAQ:DFFN) announced its earnings results on Wednesday. The company reported ($0.13) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.07), Bloomberg Earnings reports.

Shares of NASDAQ DFFN opened at $0.33 on Friday. The company has a market cap of $16.72 million, a PE ratio of -0.29 and a beta of -1.43. Diffusion Pharmaceuticals has a 1-year low of $0.31 and a 1-year high of $2.08.

DFFN has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $1.25 target price on shares of Diffusion Pharmaceuticals in a research note on Monday, August 20th. ValuEngine upgraded Diffusion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st.

TRADEMARK VIOLATION WARNING: “Diffusion Pharmaceuticals (DFFN) Announces Quarterly Earnings Results” was first reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://transcriptdaily.com/2018/11/16/diffusion-pharmaceuticals-dffn-announces-quarterly-earnings-results.html.

About Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.

Featured Article: Quiet Period

Earnings History for Diffusion Pharmaceuticals (NASDAQ:DFFN)

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply